IUPAC, Compendium of Chemical Terminology , 5th ed
A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
Journal of Nutrition and Biochemistry, 42(2), 219-228
GHK-Cu is studied in models involving collagen-associated pathways, extracellular matrix signaling, and skin-cell response
Swallow oral semaglutide first thing in the morning with no more than 4 ounces of plain water (read: not coffee)
GLP-1s not tied to suicide, self-harm According to Peter Ueda, MD, PhD , an assistant professor at Karolinska Institute in Sweden, and colleagues, the effect of GLP-1 receptor agonists on suicidality is plausible becausre the drugs have been shown to cross the blood-brain barrier. However, they also pointed out how some have hypothesized that GLP-1 receptor agonists could protect against mental illness like depression
